Principia’s Bruton tyrosine kinase (BTK) inhibitors add to Sanofi’s efforts to accelerate and build a portfolio of the next generation of transformative treatments for autoimmune diseases. BTK is present in the signaling pathways of key innate and adaptive cell types of the immune system. Being able to block or disrupt these signaling processes can help in stopping inflammation and tissue destruction related to autoimmune diseases and target some of the underlying pathophysiology.
Principia’s successful design and development of a whole portfolio of BTK inhibitors for immunology is aimed to transform the treatment for patients with immune-mediated diseases. By combining with Sanofi, the company expect to bring significant resources to expand and accelerate the potential benefits of these therapies.
The benefit of developing several BTK inhibitors will allow the company to target specific organ systems for optimal patient benefit. The merger will provide global resources to get these novel therapies to patients faster.
No of Pages : 94